ASH 2020 | The impact of pevonedistat on patient-reported outcomes in the P-2001 study
Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC shares the results of the Phase II P-2001 study (NCT02610777) of pevonedistat (P) plus azacitidine (A), compared to A alone in patients with high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or low blast acute myeloid leukemia (LB AML). The analysis explored patient-reported outcomes from quality of life (QoL) questionnaires of 112 patients, completed at various time points before, during and after treatment. Key QoL scores, including physical functioning, global health status, fatigue, and dyspnea, showed no difference in change over time between the P+A and A arms. A higher score than baseline was recorded for both groups upon achieving complete remission. Further analyses are planned to improve understanding of the effect of P on patient-reported outcomes. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Joshua Zeidner, MD, has received honoraria from AbbVie, Agios, Bristol Myers Squibb/Celgene, Daiichi-Sankyo, Genentech, Pfizer, and Takeda; consulting fees from AsystBio Laboratories, Celgene, and Takeda; research funding from AROG, Celgene, Forty Seven/Gilead, Merck, Sumitomo Dainippon Pharma, and Takeda; and has received travel reimbursement from Forty Seven and Takeda.
